Journal Articles on Mesothelioma: 'Intrapleural Chemotherapy' Category
July 26th, 2008. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
Conclusions: Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.
Posted in Chemotherapy, Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Intrapleural Chemotherapy, Peritoneal (Abdominal Mesothelioma), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 26th, 2008. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations
The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.
June 26th, 2008. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
Conclusion: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
April 10th, 2008. Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution’s Experience
Conclusions: In highly selected patients local control can be achieved with combination therapy but is accompanied by a high rate of (surgical) complications. Distant failure rates warrant further studies exploring the role of systemic chemotherapy while the use of cytoreductive surgery with intraoperative chemoperfusion for MPM is not supported.
Posted in Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Radiation, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 16th, 2008. Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma
This review summarizes relevant surgical aspects and anesthetic insights from the Brigham and Women's Hospital experience. Included are the anesthetic implications of intraoperative intracavitary hyperthermic chemotherapy in combination with extrapleural pneumonectomy - an emerging therapeutic option in the treatment of malignant pleural mesothelioma.
Posted in Chemotherapy, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Surgery, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 19th, 2007. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
In ovarian cancer the rationale for this treatment remains large but its current application is limited. Much work needs to be done to identify a proper clinical perspective on hyperthermia used with chemotherapy in patients with peritoneal surface malignancy.
July 20th, 2007. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin
Conclusions: Early cardiotoxicity is limited after this treatment modality using substantial doses of doxorubicin and cisplatin. Hence, this study suggests that intrathoracic chemotherapy with doxorubicin and/or cisplatin may be used for primary and secondary pleural malignancies, even immediately after extensive thoracic surgery, without concern of severe early cardiotoxicity.
March 14th, 2007. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment
Conclusions: With this new recurrence model for investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy. The intrapleural application of cisplatin-Vivostat® significantly reduced the extent of local recurrence.
January 26th, 2007. Diffuse malignant pleural mesothelioma
Median survival time after diagnosis was 3 (range, 0 to 51) months. Of the 11 patients, 7 (64%) died within 6 months after the first presentation, and only 1 (9%) lived longer than 2 years after diagnosis.
Posted in Biphasic or Mixed, Chemotherapy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 26th, 2006. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Conclusions: The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome. New targeted therapies are awaited for further improvements in the treatment of this disease.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Epithelioid, Full Archive, Gemcitabine (Gemzar), Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 3rd, 2006. Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
Conclusion: It was therefore concluded that hyperthermia combined with intra-thoracic chemotherapy using cisplatinum or carboplatinum may be tolerable. This approach appears effective and more acceptable for patients with MPM with pleural effusion than other multi-modality therapy.
June 6th, 2006. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
Conclusions: Intensity-modulated RT treatment for mesothelioma after EPP and adjuvant chemotherapy resulted in a high rate of fatal pneumonitis when standard dose parameters were used. We therefore recommend caution in the utilization of this technique. Our data suggest that with IMRT, metrics such as V5 and MLD should be considered in addition to V20 to determine tolerance levels in future patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, IMRT, Intrapleural Chemotherapy, Pemetrexed (Alimta), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 5th, 2006. “Therapeutic” pleural surgery
Median survival for operated mesothelioma is 19 months with a 46% five-year survival for the tumors with the best prognosis. At the present time, radical surgical resection is the basis of local treatment for pleural mesothelioma.
April 1st, 2006. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma
Conclusion: Pleurectomy and high-dose intraoperative intracavitary hyperthermic cisplatin lavage is feasible in this patient population withrestricted surgical options. An apparent dose-related survival benefit warrants further study.
March 7th, 2006. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma
Conclusions: Intrapleural administration of cisplatin with the carrier Vivostat significantly provides sustained higher platinum concentrations up to 1 week in tissue in comparison with application of cisplatin solution without conferring systemic toxicity in this model.
November 1st, 2004. Patterns of failure following surgical resection for malignant pleural mesothelioma
Further clinical studies are needed for all patients with mesothelioma to define the optimum surgery and duration and types of adjuvant therapy. The appropriate multimodality approaches most likely will differ based on disease stage, histology, and patient performance status.
Posted in Chemotherapy, Cisplatin (Platinol ®), Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Intraperitoneal Chemotherapy, Intrapleural Chemotherapy, Pemetrexed (Alimta), Pleural, Pleurectomy/decortication, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
